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INTRODUCTION: Isolated pulmonary metastases from soft tissue sarcomas occur in 20-50% of these (the issue is about
metastases, notlung cancer)patients, and70%of these patients will present disease limitedonlyto the lungs.Surgical
resection is well accepted as a standard approach to treat metastases from soft tissue sarcomas isolated in the lungs,
andmany studiesinvestigatingthis techniquehave reportedanoverall5-year survivalrangingfrom 30-40%.Themost
consistent predictor of survival in these patients is complete resection. The aim of the present study was to determine
the demographics and clinical treatment-related variables associated with long-term (90-month) overall survival in
patients with lung metastases undergoing pulmonary metastasectomy from soft tissue sarcomas.
METHODS: We performed a retrospective review of patients admitted in the Thoracic Surgery Department with
lung metastases who underwent thoracotomy for resection following treatment of the primary tumor. Data
regarding primary tumor features, demographics, treatment, and outcome were collected.
RESULTS: One hundred twenty-two thoracotomies and 273 nodules were resected from 77 patients with previously
treated soft tissue sarcomas. The median follow-up time of all patients was 36.7 months (range: 10-138 months). The
postoperative complication rate was 9.1%, and the 30-day mortality rate was 0%. The 90-month overall survival rate
for all patients was 34.7%. Multivariate analysis identified the following independent prognostic factors for overall
survival: the number of metastases resected, the disease-free interval, and the number of complete resections.
CONCLUSION: These results confirm that lung metastasectomy is a safe and potentially curative procedure for
patients with treated primary tumors. A select group of patients can achieve long-term survival after lung resection.
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INTRODUCTION
Sarcomas are a group of very uncommon malignant
tumors that compromise 1% of all adult malignancies.
1
Approximately 11,590 new diagnoses and 3,560 deaths from
soft tissue sarcomas (STS) and bone sarcomas occur
annually in the United States.
1 Isolated pulmonary metas-
tases from STS occur in 20-50% of these patients, and 70% of
these patients will have disease limited only to the lungs.
2
Once systemic metastatic disease develops, the prognosis is
typically poor.
3 Patients with extremity sarcomas are more
likely to develop distant metastatic disease as the initial site
of recurrence, whereas those with retroperitoneal and
visceral sarcomas tend to present local recurrence.
4
Although considerable progress has been achieved in
both chemotherapy and surgical treatment of STS, pulmon-
ary metastases remain a major cause of mortality. Given that
a diagnosis of pulmonary metastases significantly affects
outcome, treatment and prognosis, the detection of such
pulmonary metastases is of vital importance.
5
Surgical resection is well accepted as a standard approach
for the treatment of metastases from STS isolated to the
lungs, and many studies investigating this technique have
reported an overall 5-year survival ranging from 30-40%
6,7.
Chemotherapy has not been shown to increase survival
following the complete resection of pulmonary metastases.
6
Pulmonary metastasectomy is currently indicated for
patients with the following criteria: primary tumor con-
trolled, possibility of complete resection verified by com-
puted tomography (CT) of the chest, pulmonary function
and performance status compatible with the proposed lung
resection, and lack of another available treatment that
would be more effective than the surgical procedure.
8
Although the results obtained for pulmonary metasta-
sectomy are encouraging, there is a need to better select and
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871identify the patients who would benefit most from surgical
removal of pulmonary metastases to avoid unnecessary
surgical procedures. Many authors have reviewed their
experience in an attempt to clearly identify the variables
associated with better survival. Important predictors of
survival include disease-free interval, histology of the tumor,
the number of metastases and complete resection.
5-7 Among
these, the most consistent predictor of survival is complete
resection.
6,7,9 The number of metastatic nodules and their
impact on survival was initially considered to be an
independent predictor of survival.
10 However, if complete
resection can be achieved, the number of pulmonary meta-
static nodules does not seem to influence survival.
6,7,11
Since the early 1990s, our institution has employed a
prospective protocol-oriented approach for the treatment of
patients with resectable lung metastases to define factors
related to outcome following lung metastasectomy.
The aim of this study was to report the outcomes of
patients with pulmonary metastases from STS who were
submitted to surgical resection and to identify prognostic
factors that affect overall survival in a group of patients
from a single institution.
MATERIAL AND METHODS
We retrospectively analyzed 77 patients with previously
treated STS who had developed pulmonary metastases. The
patients were referred to the Thoracic Surgery Department
of AC Camargo Hospital between 1990 and 2006. All
patients were included and followed according to a
prospective protocol. This study was approved by the ethics
review board at our institution.
Data were collected following a medical record review of
each patient. The following characteristics of the primary
tumors were recorded: primary tumor site (extremity vs.
others), completeness of surgical resection, histological type
and grade, and neoadjuvant and adjuvant treatment.
All patients were evaluated for the presence of lung
nodules before treatment of the primary STS, followed by
evaluations at routine follow-up appointments. The disease-
free interval was defined as the time period between
treatment of the primary tumor and the diagnosis of
pulmonary metastases.
Patients with the following characteristics were consid-
ered eligible for pulmonary resection: 1) primary tumor
controlled, 2) nodules confined to the lung parenchyma, 3)
nodules that were amenable to complete surgical resection,
4) pulmonary function and clinical condition compatible
with the scheduled operation, and 5) the unavailability of
more effective treatment options for the patient at that
time.In addition to the evaluations, we collected variables
related to the pulmonary metastases, including the number
of pulmonary nodules on the CT scan, the number of
malignant pulmonary nodules resected, the size of the
largest nodule resected and the laterality of the pulmonary
nodules.
All patients underwent a chest CT scan prior to surgery to
evaluate the possibility of complete resection. Radiological
characteristics were analyzed in each patient as follows: the
number of pulmonary nodules, the size of the largest nodule
and the laterality of the nodules. The number of nodules
reported in this study was the final number confirmed by
the surgeon after complete resection.
A staged lateral thoracotomy was employed when
bilateral nodules were discovered at admission. This
procedure was typically initiated on the side where
complete resection was deemed more difficult and included
the number and size of the nodules identified by chest CT
scan, the anatomical position of one or more nodules
relative to the pulmonary hilum, and the potential need
for a more complex and extensive lung resection.
Patients underwent surgery with general anesthesia and
single lung ventilation. In all cases, we attempted a
complete resection while preserving the lung parenchyma
with a margin of 10 mm. A one-sided lateral thoracotomy
was performed. Even in cases of bilateral disease, we
routinely performed a staged thoracotomy. At our institu-
tion, mediastinal lymph node dissection is not routinely
performed in patients with lung metastases. In cases of a
single pulmonary nodule at surgery, frozen sections were
collected. If the histological evidence suggested the possi-
bility of primary lung cancer, the patient was submitted to
lobectomy with radical mediastinal lymph node dissection
whenever possible.
The date of surgery, type of resection (complete or
incomplete), number of malignant or benign nodules
resected, size of the largest nodule, and type of lung
resection (wedge, segmentectomy, lobectomy or pneumo-
nectomy) were documented.
Some patients received chemotherapy based on the
discretion of the medical oncologist, before or after surgical
resection of the lung metastases. The type of radiological
response (partial, stable, complete, or progression) as
defined by RECIST
12 criteria was documented.
After surgery, the patients were discharged from the
hospital following chest tube removal and in good clinical
condition. After hospital discharge, the patients were
followed-up with clinical and radiological examinations
(chest X-ray and CT scan) every three months during the
first two years and every six months subsequently until the
fifth year. An annual radiological (chest X-ray) follow-up
was performed after five years. The observed postoperative
complications were fever . 38˚C, bleeding, air leakage for
more than seven days, intensive care unit stay for more than
two days, cardiac complications (arrhythmia, ischemia, and
infarction), pulmonary atelectasis, embolism or respiratory
failure, stroke and infection. Recurrence was recorded when
new lesions were identified in the lung or elsewhere.
Whenever necessary, a histological confirmation of the new
tumor was performed. If the recurrence was confined to the
lungs and if the nodules were considered resectable by the
thoracic surgeon, the patient was offered another attempt at
complete disease resection.
Statistical Analyses
The main outcome evaluated was death associated with
the tumor. Survival was calculated from the time of
resection of the primary tumor and from the time of first
metastasectomy to death or until the last follow-up. Overall
survival was estimated using Kaplan-Meier
13 analysis. The
log-rank and Breslow tests were used to compare survival
differences for each variable.
Multivariate analyses to determine the independent
prognostic factors for overall survival were performed
using the Cox proportional hazard model
14 as identified
by the univariate analyses. Survival time was determined
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performed, with time zero denoting the first thoracotomy.
Statistical analyses were performed using SPSS 11.5 for
Windows. Significant differences were defined as p,0.05.
RESULTS
The patients included in this retrospective study (n=77)
underwent a total of 122 thoracotomies (mean of 1.6
thoracotomies / patient); 273 nodules were resected, with
a mean of 3.5 nodules per thoracotomy. Five of the nodules
were carcinomas and were treated as primary lung tumors,
and more than four nodules were resected in each of 18
(18.1%) patients.
According to the primary STS, 66 (85.7%) patients had
extremity tumors, and 11 patients (14.3%) had visceral or
retroperitoneal tumors. In 64 patients (83.1%), the primary
STS histology (Table 1) and grade (Table 2) were registered
as well. In the 13 remaining patients, we could not find
sufficient detailed information regarding the histological
type and grade of the primary tumors in the medical records
because the primary tumors of these patients had been
resected at other institutions. Based on the final confirma-
tion of sarcomas from the pathology of the pulmonary
metastases, these tumors were classified as undetermined
and excluded from statistical analyses in which histology
was considered.
The median follow-up time was 36.7 months (range: 10-
138 months). Twenty-nine patients were alive at the time of
the final analyses, and 13 (16.9%) showed no evidence of
disease. Thirty patients (39%) died due to metastatic STS,
and 18 (23.4%) patients were considered lost to follow-up
after missing two medical evaluations.
The postoperative complication rate was 9.1% (n=7).
More than one complication occurred in some patients,
including fever, atelectasis, prolonged air leakage (. 7 days),
infection and a prolonged hospital stay (. 30 days). There
was no 30-day mortality associated with the surgery used in
this series.
The median overall survival for all patients was
36.7 months, with an estimated 5-year survival rate of
34.7% (Figure 1). The median survival for patients with one,
two, three or more pulmonary metastasis resections was
15.1, 44.8 and 48.1 months, respectively. No significant
difference in survival was detected between the groups with
respect to the number of thoracotomies (p=0.07).
All other factors evaluated in the univariate analyses,
including the response to adjuvant chemotherapy, type of
resection, number of resected nodules, laterality of the
nodules on the CT scan, number of thoracotomies and size
of the largest nodule resected, were not statistically
significant (p.0.05). The patient characteristics and uni-
variate analyses are shown in Table 3. Multivariate analyses
identified the number of pulmonary nodules resected
(p=0.003), the disease-free interval (p,0.001) and complete
resection (p,0.001) as independent prognostic factors for
overall survival (Table 4).
DISCUSSION
The resection of pulmonary sarcomatous metastasis
remains the cornerstone for treatment of isolated pulmonary
metastases in patients with STS.
14 In the absence of other
effective treatments and of contraindications, patients with
lung metastases from STS benefit from surgical therapy.
16,17
Approximately 20-30% of patients undergoing pulmo-
nary resection can experience long-term survival.
5,6,18
Improved survival following the resection of lung metas-
tases has increased the surgical indications for such lesions,
thus confirming that surgery itself affects the outcomes of
patients who are candidates for a complete resection of
nodules confined to the lungs. Therefore, resectability
should be evaluated preoperatively according to specific
criteria. The recent introduction of positron emission
tomography using 18-fluorodeoxyglicose (FDG PET-CT)
has proven to be of clinical value for the proper staging of
cancer patients to better select the best candidates for
resection. According to Pastorino et al., this method can
eliminate 21% of patients who are otherwise considered as
Table 1 - Histologic type in 64 patients submitted to
pulmonary metastasectomy.
Histology of the primary tumor n %
Malignant fibrous histiocytoma 15 23.4
Liposarcoma 11 17.1
Fibrosarcoma 10 15.6
Synovial sarcoma 9 14.0
Leiomyosarcoma 8 12.5
Spindle cell sarcoma 5 7.8
Epithelioid sarcoma 2 3.1
Rhabdomyosarcoma 2 3.1
Angiosarcoma 1 1.5
Hemangiopericytoma 1 1.5
Undetermined 13 18.1
Total 77 100
Table 2 - Grade of STS in 64 patients submitted to
pulmonary metastasectomy.
GRADE n %
G3 50 78.1
G2 8 12.5
G1 6 9.3
Undetermined 13 18.1
Total 77 100
Figure 1 - Overall survival rates for all patients n=77.
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19 Unfortunately, PET-CT was not
available at our institution for most of the patients in this
study.
Several studies have been conducted to identify prog-
nostic factors for pulmonary metastasectomy in STS.
5-7,17
The factors evaluated included the disease-free interval
number of metastatic lesions resected, tumor doubling time,
laterality, number of thoracotomies and resectability of the
lesions.
20-23 STSs are an extremely heterogeneous group of
tumors with a variable biological behavior. Therefore, the
histological type and grade of malignancy are the most
important prognostic factors in the treatment of primary
tumors.
24 Moreover, other studies have found histology to
be predictive of pulmonary metastasis, resectability, and
overall survival in extremity STS.
6,25
The 77 patients included in this study underwent 122
thoracotomies for the treatment of lung metastases. The
estimated 5-year overall survival of our patients was 34.7%
at an average follow-up of 36.7 months. This outcome is
similar to previous reports .
5,7,9 In a review of the National
Cancer Institute, the overall 5-year survival rate was 28%,
with a 35% 3-year survival rate for patients who underwent
complete resection. In that series, patients who experienced
incomplete resection demonstrated a median survival of
9 months.
26 With a median follow-up period of 27 months,
the International Registry of Pulmonary Metastases repor-
Table 3 - Univariate analyses and characteristics of the 77 patients submitted to pulmonary metastasectomy.
Variables n Median survival (months) p (Log-rank)
Age (years)
,45 37 (48.1%) 30.3 0.326
$45 40 (51.9%) 52.5
Gender
Male 37 (48.1%) 36.7 0.152
Female 40 (51.9%) 33.9
Primary tumor site
Extremities 66 (85.7%) 38.2 0.389
Others 11 (14.3%) 17.0
Neoadjuvant chemotherapy
Yes 26 (33.8%) 12.5 0.018
No 51 (66.2%) 45.2
Adjuvant chemotherapy
Yes n=18 (23.4%) 25.4 0.077
No 59 (76.6%) 38.2
Disease-free interval (months)
#16 31 (40.3%) 8.3 ,0.001
.16 46 (59.7%) 60.0
Number of thoracotomies
1 35 (48.6%) 15.1 0.077
2 24 (33.3%) 44.8
$3 13 (18.1%) 48.1
Laterality of the nodules
Right 24 (31.2%) 35.0 0.076
Left 15 (19.5%) 36.7
Bilateral 38 (49.4%) 36.0
Complete resection at last thoracotomy
Yes 61 (79.2%) 44.8 ,0.001
No 16 (19.0%) 9.5
Number of malignant nodules resected
1 43 (55.9%) 38.2 0.930
2-4 20 (26.0%) 24.8
.4 14 (18.1%) 36.7
Type of resection
Segmentectomy/wedge 63 (81.8%) 36.7 0.944
Lobectomy 12 (15.6%) 35.0
Biopsy 2 (2.6%) 9.5
Diameter of the largest nodule resected
#2 cm 21 (27.4%) 62.2 0.231
.2-4 cm 38 (49.8%) 44.8
.4 cm 18 (22.8%) 33.9
Table 4 - Multivariate analyses of the overall survival.
Variables p
Disease-free interval (.16 months) ,0.001
Number of malignant resected nodules (,4) 0.003
Complete resection ,0.001
Pulmonary metastasectomy
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lung metastases of 30% and 22%, respectively .
7 However,
this result does not compare to the 14-21% overall survival
reported by some studies with longer follow-up periods.
6
Several reports have demonstrated the prognostic impor-
tance of the number of nodules detected in the preoperative
workup. The sensitivity of detecting pulmonary nodules
varies depending on the technique used.
23 In a prospective
study including 182 patients with cancer and pulmonary
metastases by Younes et al., CT scan detected the exact
number of nodules resected in 47% of the patients.
However, CT scan underestimated the actual number of
lung nodules found during surgery in 28% of the cases and
overestimated that number in 24%.
27 In the present study,
we discovered a poorer outcome in patients in which $ 4
nodules had been resected, as shown in the multivariate
analysis.
For some authors, the number of pulmonary metastases
does not preclude resection because the ability to achieve
complete resection is of greater prognostic value than the
number of lesions removed.
28 In a review of the European
Organization for Research and Treatment of Cancer
(EORTC) database, the majority of patients undergoing
resection (53%) had only one lesion, although 15% of the
patients had more than four lesions at the time of
pulmonary metastasectomy.
29
Previous studies have examined the number of nodules
resected and the presence of unilateral and bilateral
metastatic disease as prognostic factors. Casson et al.
demonstrated that patients with three or fewer nodules
survived significantly longer than did patients with four or
more nodules resected
9. Similar findings have been noted
by Putnam et al.
5 who found that patients with four or fewer
nodules survived longer than did patients with more than
four nodules resected. The same group demonstrated that
unilateral versus bilateral disease is not a significant
indicator for prognosis. In most studies published to date,
no differences have been observed in the survival of patients
with metastases confined to one lung compared to bilateral
lesions, despite the histology of the primary tumor
7. The
current study did not identify laterality as an independent
indicator of prognosis.
In the present study, the number of nodules resected had
a significant effect on long-term survival in both univariate
and multivariate analyses (p=0.003). Although the max-
imum number of pulmonary metastases often predicts
survival,
5,10 subgroup analyses have found that complete
resection is a stronger predictor of survival, regardless of the
number or size of the nodules.
31
Based on multivariate analysis, patients with synchro-
nous metastases (DFI,16 months) presented with a
significantly lower survival rate (p,0.001) than did patients
with metachronous disease, as reported in other stu-
dies.
6,7,21,22,32 The correlation between DFI and survival is
not consistent in the published data. Depending on the
study, DFI ranging from 8 months to as long as 5 years have
been a significant prognostic factor; however, the results are
vague and inconclusive according to some authors.
29,31
Previous reports have been unable to consistently
demonstrate a correlation between the primary site of STS
and survival.
29,33 In the current series, univariate analyses
demonstrated better survival for patients with non-extre-
mity primary tumors. In the multivariate analyses, however,
the site of the resected primary tumor did not affect the
long-term survival of patients submitted to pulmonary
metastasectomy.
6 Similarly, no significant effect on outcome
was observed between extremity tumors and those present
in other primary sites.
Preoperative and postoperative systemic therapy had no
significant effect on the long-term survival rate in this
patient population, which is consistent with previously
published data.
34,35 Although the patients (n=26) submitted
to neoadjuvant treatment with chemotherapy prior to
primary tumor resection demonstrated a numeric difference
in the univariate analyses (p=0.018), this variable did not
have a significant effect in the multivariate analyses.
Complete resection was achieved in 62 patients (80.5%).
This variable was a strong prognostic indicator in the mul-
tivariate analyses (p,0.001), which is consistent with
previous reports.
5-7,10,11,21,22 The median survival for patients
who underwent complete resection was 44.8 months, as
compared to 9.5 months in the group who underwent
incomplete resection (n=15). In the present study, 15
(19.5%) patients were resubmitted to surgery for recurrent
metastases, which ranged from one to four thoracotomies for
complete resection. Curiously, these patients demonstrated
better survival (median survival: 48.1 months) than did those
who underwent one thoracotomy for metastasectomy (med-
ian survival: 15.1 months), which is consistent with pre-
viously published data.
21,22,31,36 Weiser et al. investigated a
series of 86 patients who had undergone repeat resections. A
poorer survival after repeat resection was associated with the
following factors: more than three nodules, lesions larger
than 2 cm, and high-grade histopathology. The presence of 0-
1 adverse factors was associated with a disease-specific
survival of 65 months. In comparison, the presence of 2-3
factors was associated with a disease-specific survival of
10 months.
37
The type of surgical resection and the total number of
thoracotomies failed to significantly influence patient out-
come. The majority of our patient population (81.8%)
underwent a sublobar resection, and ten (15.6%) patients
required a lobectomy for complete resection. As reported
previously, limited resection with lung parenchyma pre-
servation is considered adequate to achieve clear margins
and thus to provide local control of the disease. Recently,
Cerfolio et al. showed that among 37% of patients who were
candidates for video-assisted thoracic surgery (VATS),
intraoperative palpation during a thoracotomy detected
more nodules than had been identified using preoperative
imaging by CT scan.
38 There may be a role for minimally
invasive surgery in the pulmonary metastasectomy setting;
however, additional prospective studies are required.
Although randomized controlled studies comparing
observations to surgery are impossible, the current data
suggest that the patients most likely to benefit from
metastasectomy have a longer disease-free interval, single
metastases, and complete resection of the metastases. The
administration of neoadjuvant or adjuvant therapy may
allow for further prolonged survival in some instances,
despite the finding that surgery alone fails to treat lung
metastases in the majority of patients. It should be
emphasized that surgery does not change the biology of
the tumor or the metastatic process, and a definitive cure
for most patients represents the combination of host
histology, tumor spread, response to systemic therapy,
and surgical resection, which together render the patient
free of disease.
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875CONCLUSION
This retrospective study identified a group of patients
who may benefit from pulmonary metastasectomy. All
patients with resectable nodules evaluated by CT scan and
selected by the inclusion criteria should be considered as
candidates for surgical resection because they might reveal
an interesting overall survival, as shown by the present
study.
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